Accessing Innovative Orphan Therapies in China: Local Advancements
These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China
In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance schemes, the commercial
Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market
Bi Jingquan, previously at the helm of the China Food and Drug Administration and instrumental in regulatory overhauls that transformed
China Market Access Pathways for Innovative Medicines Infographic
Breaking from my usual bi-weekly newsletters, I have a valuable resource for you: an infographic detailing China Market Access Pathways
Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China
“In my capacity as a researcher, I've had experience in both scientific research and drug development. Additionally, as
Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways
Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.
Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities
In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations
Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect
